Synergistic inhibition of lipid peroxidation by vitamin E and a dopamine agonist, cabergoline

Neurological Research

Volumn 26, Issue 4, 2004, Pages 418-421

  Sohmiya, Makoto ^a   Tanaka, Makoto ^a   Okamoto, Koichi ^a   Fujisawa, Akio ^b   Yamamoto, Yorihiro ^b  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF TECHNOLOGY   (Japan)

Author keywords

Antioxidant; Cabergoline; Dopamine agonist; Parkinson's disease; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CABERGOLINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LIPOSOME; PHOSPHATIDYLCHOLINE; UBIQUINOL 10; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG; WATER;

ANTIOXIDANT ACTIVITY; ARTICLE; DRUG POTENTIATION; DRUG SOLUBILITY; LIPID PEROXIDATION; NEUROPROTECTION; OXIDATION; PARKINSON DISEASE; SUBSTANTIA NIGRA;

ANTIOXIDANTS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ERGOLINES; KINETICS; LIPID PEROXIDATION; LIPOSOMES; TIME FACTORS; VITAMIN E;

EID: 2942623606     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164104225016029     Document Type: Article

References (20)

1. Ehringer H, Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen system. Klin Wochenschr 1960; 38: 1236-1239
2. Teychenne PF, Calne DB, Leigh PN, et al. Idiopathic parkinsonism treated with bromocriptine. Lancet 1975; 2: 473-476
3. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 2000; 7: 240-250
4. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997; 49: S26-S33
5. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998; 44: S167-S174
6. Yoshikawa T, Minamiyama Y, Naito Y, et al. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994; 62: 1034-1038
7. Gomez-Vargas M, Nishibayashi S, Asanuma M, et al. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res 1998; 790: 202-208
8. Finotti N, Castagna L, Moretti A, et al. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res 2000; 42: 287-291
9. Yoshioka M, Tanaka K, Miyazaki I, et al. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res 2002; 43: 259-267
10. Yoshida T, Tanaka M, Suzuki Y, et al. Antioxidant properties of cabergoline; inhibition of brain auto-oxidation and superoxide production of microglias in rats. Neurosci Lett 2002; 330: 1-4
11. Yamamoto Y, Komuro E, Niki E. Antioxidant activity of ubiquinol in solution and phosphatidylcholine liposome. J Nutr Sci Vitaminol 1990; 36: 505-511
12. Singleton WS, Gray MS, Brown ML, et al. Chromatographically homogeneous lecithin from egg phospholipids. J Am Oil Chem Soc 1965; 42: 53-56
13. Kohen R, Yamamoto Y, Cundy KC, et al. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci USA 1988; 85: 3175-3179
14. Yamamoto Y, Maita N, Fujisawa A, et al. A new vitamin E (a-tocomonoenol) from eggs of the Pacific salmon Oncorhynchus keta. J Nat Prod 1999; 62: 1685-1687
15. Barclay LRC, Ingold KU. The autoxidation of a model membrane. A comparison of the autoxidation of egg lecithin phosphatidylcholine in water and in chlorobenzene. J Am Chem Soc 1981; 103: 6478-6485
16. Yamamoto Y, Niki E, Kamiya Y, et al. Oxidation of phosphatidylcholines in homogeneous solution and in water dispersion. Biochim Biophys Acta 1984; 795: 332-340
17. Dostet P, Hagberg G, Battaglia R, et al. Distribution and metabolism of 14C-cabergoline in the rat brain. Pharmacol Res 1997; 35: 202
18. Shoulson I, Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Ann Neurol 1998; 44: S160-S166
19. Tanaka M, Sotomatsu A, Kanai H, et al. Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by dopa and iron. Neurosci Lett 1992; 140: 42-46
20. Dexter DT, Nanayakkara I, Goss-Sampson MA, et al. Nigral dopaminergic cell loss in vitamin E deficient rats. Neuroreport 1994; 5: 1773-1776